<DOC>
	<DOC>NCT02550613</DOC>
	<brief_summary>The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.</brief_summary>
	<brief_title>Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Prior Informed Consent Form 2. At least one measurable tumor, according to RECIST version 1.1. 3. Age &gt; 20 years. 4. ECOG performance status 0 or 1. 5. Life expectancy &gt; 3 months. 6. Confirmed Diagnosis of HCC 7. Adequate renal function (Serum creatinine â‰¦ 1.5 x upper limit of normal). 1. Age &lt;20 years old 2. Pregnancy 3. Contraindication for MRI: claustrophobia or MR noncompatible devices 4. Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre &gt; 2.0) 5. History of other malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>MR/PET, hepatocellular carcinoma, HCC</keyword>
</DOC>